Search clinical trials for: Afatinib - 1B

Total 2363 results

Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

China
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University... and other collaborators

Completed

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Leukemia, Myeloid, Chronic

United States
Nanfang Hospital of Southern Medical University

Unknown

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Leukemia, Lymphoblastic, Acute

China
Bayer

Terminated

Rehabilitation Study in MS Patients

Multiple Sclerosis, Relapsing-Remitting

France
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
University of Chicago
National Cancer Institute (NCI)

Terminated

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
Bayer

Completed

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis (ROBUST)

Multiple Sclerosis, Relapsing-Remitting

United States
University of North Carolina, Chapel Hill

Completed

Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

Multiple Sclerosis

United States
Boehringer Ingelheim

Completed

Long-term Observation PMS for Afatinib

Carcinoma, Non-Small-Cell Lung

Japan
University of Jena
Novartis Pharmaceuticals; Ludwig-Maximilians - University of Munich

Active, not recruiting

Frontline Asciminib Combination in Chronic Phase CML (CMLXI)

Chronic Myeloid Leukemia

Germany
Medical University of South Carolina
Boehringer Ingelheim

Withdrawn

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma (IFNa)

Melanoma | Sarcoma | Lymphoma | Kidney Cancer | Breast Cancer | Multiple Myeloma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Universitätsklinikum Hamburg-Eppendorf
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Refractory Cancer

Germany
Fudan University

Unknown

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Tumor

China
Bayer

Completed

Depression and Fatigue in MS Patients Treated With Betaferon. (FADO)

Multiple Sclerosis

Poland
Bayer

Completed

BENEFIT Extension Study

Multiple Sclerosis

Switzerland, Poland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Slovenia, Israel, Belgium, Denmark, Netherlands, Canada, Norway, Finland
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Boehringer Ingelheim

Completed

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Non-squamous, Non-Small Cell Lung Cancer

Japan
Boehringer Ingelheim

No longer available

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Solid Tumors
University College, London
Boehringer Ingelheim

Completed

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (TIMELY)

Carcinoma, Non-Small-Cell Lung

United Kingdom
Boehringer Ingelheim

Completed

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Boehringer Ingelheim

Terminated

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Neoplasms

United States, Taiwan
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Enrolling by invitation

BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) (BEAR)

Esophageal Squamous Cell Carcinoma (ESCC)

Taiwan
Sheba Medical Center

Unknown

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NSCLC

Israel
Bayer

Completed

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Germany, Austria, United Kingdom, Israel, Belgium, Finland
Bayer

Completed

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Multiple Sclerosis

Belgium, Italy, Spain, France, Germany, Canada, Switzerland, Austria, Denmark, Hungary, Netherlands, Poland, Israel, United Kingdom, Finland, Sweden, Norway, Czech Republic, Portugal, Slovenia
Janssen Research & Development, LLC

Completed

Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States
Southern Illinois University

Completed

Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients

Carcinoma

United States
Elevar Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States, Korea, Republic of
Shanghai Jiao Tong University Affiliated Sixth...

Unknown

A Phase II Study of Apatinib in STS Patients

Soft Tissue Sarcoma
Pfenex, Inc

Completed

Comparison Study of PF530 and Betaferon in Healthy Subjects

Multiple Sclerosis

Australia
Bayer

Completed

Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients

Multiple Sclerosis

France
Bayer

Completed

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Relapsing-Remitting Multiple Sclerosis

Germany
Shanghai Chest Hospital

Not yet recruiting

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NRG1-fused Non-small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Bayer

Completed

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (INFLUENCE)

Multiple Sclerosis

Poland
Bayer

Completed

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Multiple Sclerosis

China
Bayer

Withdrawn

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis

Sweden, Denmark
Bayer

Completed

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy

Heart Diseases | Cardiomyopathies

Italy, Spain, Germany, Poland, United Kingdom, Sweden, France
Wei Zhao
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Hematological Neoplasms

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Head and Neck Squamous Cell Carcinoma

United States
Augusta University
H. Jean Khoury Cure CML Consortium

Recruiting

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)

Leukemia, Myeloid | Chronic Myeloid Leukemia, Chronic Phase | Adult CML | Leukemia,Myeloid, Chronic

United States
Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma

China
Boehringer Ingelheim

Completed

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, Taiwan, Singapore, Japan
Hellenic Cooperative Oncology Group
Boehringer Ingelheim

Completed

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer (A-GAPP)

Gastric Cancer | Gastroesophageal Junction Cancer

Greece
Yonsei University

Completed

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

NSCLC
Tianjin Medical University Cancer Institute and...

Unknown

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer

China

Search clinical trials for: Afatinib - 1B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations